首頁 > 市場調查報告書 > 製藥

循環系統

肺動脈高壓市場規模、佔有率和成長分析（按藥物類別、類型、給藥途徑、分銷管道和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1896848

肺動脈高壓市場規模、佔有率和成長分析（按藥物類別、類型、給藥途徑、分銷管道和地區分類）－2026-2033年產業預測

Pulmonary Arterial Hypertension Market Size, Share, and Growth Analysis, By Drug Class (Endothelin Receptor Antagonists, PDE-5 Inhibitors), By Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球肺動脈高壓 (PAH) 市場規模預計在 2024 年達到 82 億美元，從 2025 年的 86.3 億美元成長到 2033 年的 130.5 億美元，在預測期（2026-2033 年）內複合年成長率為 5.3%。

市場分析顯示，肺動脈高壓 (PAH) 市場的成長主要受以下因素驅動：該疾病盛行率不斷上升、政府對孤兒藥研發的大量投資以及人口快速老化。 PAH 的特徵是由於血管重塑導致肺小動脈阻力增加，據報導其盛行率在每 10 萬人中為 0.4% 至 1.4%。此外，全球約有 12.8 億 30 至 79 歲的人患有高血壓，其中大多數生活在中低收入國家。這一日益嚴重的健康危機與降低高血壓盛行率這一全球非傳染性疾病控制的關鍵目標一致，凸顯了 PAH 市場對有效治療方法日益成長的需求。

全球肺動脈高壓市場促進因素

肺動脈高壓（PAH）是一種進行性性疾病，會導致肺部動脈血壓升高。由於人口老化、肥胖率上升以及診斷技術的進步等因素，全球PAH發生率呈上升趨勢。隨著越來越多的患者被發現和確診，這些趨勢可能會推動對有效PAH治療方法的需求不斷成長。這些因素共同凸顯了開發創新解決方案和治療方法以應對全球PAH挑戰的必要性。

全球肺動脈高壓 (PAH) 市場阻礙因素

由於肺動脈高壓 (PAH) 的罕見性，全球 PAH 市場面臨嚴峻挑戰。與其他慢性疾病相比，PAH 患者數量相對較少，有限的患者群體可能會對 PAH 相關藥物的商業性前景產生負面影響，並抑制研發投資。 PAH 的診斷較為複雜，可能需要進行多項檢查，例如心臟超音波圖和右心導管檢查，這使得診斷過程較為繁瑣。此外，PAH 的症狀，例如疲勞和呼吸困難，通常特異性，並且可能與其他多種疾病有關，這可能導致誤診和延誤治療。

全球肺動脈高壓（PAH）市場趨勢

全球肺動脈高壓 (PAH) 市場正經歷著向個人化醫療的重大轉變，這主要得益於技術進步和對疾病遺傳基礎的深入了解。隨著越來越多的公司尋求發現能夠準確預測疾病進展和治療反應的生物標記物，這一趨勢正推動研發投入的增加。此外，針對特定基因突變的治療方法也日益受到關注，這些療法已顯著改善了治療效果和患者預後。這些創新有望推動市場成長，反映出市場對滿足 PAH 患者獨特需求的個人化治療方案的需求日益成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

United Therapeutics Corporation（United States）
Bayer AG（Germany）
GlaxoSmithKline plc（United Kingdom）
Gilead Sciences, Inc.（United States）
Novartis International AG（Switzerland）
Pfizer Inc.（United States）
Merck & Co., Inc.（United States）
Bristol-Myers Squibb Company（United States）
Teva Pharmaceutical Industries Ltd.（Israel）
Viatris Inc.（United States）
Sun Pharmaceutical Industries Ltd.（India）
Alembic Pharmaceuticals Ltd.（India）
Aerami Therapeutics Holdings Inc.（United States）
Asklepion Pharmaceuticals LLC（United States）
Keros Therapeutics（United States）
Liquidia Corporation（United States）
Ferrer（Spain）
Gossamer Bio（United States）

結論與建議

簡介目錄

Product Code: SQMIG35H2222

Global Pulmonary Arterial Hypertension Market size was valued at USD 8.2 Billion in 2024 and is poised to grow from USD 8.63 Billion in 2025 to USD 13.05 Billion by 2033, growing at a CAGR of 5.3% during the forecast period (2026-2033).

Market insights indicate that the growth of the pulmonary arterial hypertension (PAH) sector is significantly propelled by the increasing incidence of the condition, substantial government investments in orphan drug development, and a burgeoning elderly population. PAH is characterized by elevated resistance in pulmonary arterioles due to vascular remodeling, with a reported prevalence ranging from 0.4% to 1.4% per 100,000 individuals. Furthermore, a considerable global population of approximately 1.28 billion individuals aged 30-79 suffers from hypertension, predominantly found in low- and middle-income nations. This growing health crisis aligns with international objectives targeting a reduction in hypertension prevalence as a key component of the response to non-communicable diseases, underscoring the increasing demand for effective treatments within the PAH market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pulmonary Arterial Hypertension market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pulmonary Arterial Hypertension Market Segments Analysis

Global Pulmonary Arterial Hypertension Market is segmented by Drug Class, Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs and SGC Stimulators. Based on Type, the market is segmented into Branded and Generics. Based on Route of Administration, the market is segmented into Oral, Intravenous/ subcutaneous and Inhalational. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pulmonary Arterial Hypertension Market

Pulmonary arterial hypertension (PAH) is a rare and progressive disease marked by heightened blood pressure within the arteries that transport blood to the lungs. The global incidence of PAH is on the rise, driven by factors such as an aging population, increasing obesity rates, and advancements in diagnostic capabilities. These trends are likely to foster a growing demand for effective PAH treatments, as more individuals are identified and diagnosed with this condition. The combination of these elements underscores the necessity for innovative solutions and therapies to address the challenges posed by PAH on a worldwide scale.

Restraints in the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market faces significant challenges due to the rarity of the disease, resulting in a relatively small patient population when compared to other chronic conditions. This limited patient base can adversely affect the commercial prospects of PAH-related medications, deterring investment in their development. Diagnosing PAH is complex and requires multiple tests, such as echocardiograms and right heart catheterizations, which can complicate the process. Furthermore, the symptoms of PAH, including fatigue and shortness of breath, are often non-specific and may be linked to various other illnesses, which can lead to misdiagnosis or delays in appropriate treatment.

Market Trends of the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market is witnessing a significant shift towards personalized medicine, driven by technological advancements and a deeper understanding of the genetic underpinnings of the disease. This trend is fostering increased investments in research and development as companies strive to discover biomarkers that enable precise predictions of disease progression and treatment responses. Additionally, the focus on therapies targeting specific genetic mutations is gaining momentum, enhancing treatment efficacy and patient outcomes. With these innovations, the market is anticipated to expand, reflecting a growing demand for tailored therapeutic approaches that meet the unique needs of PAH patients.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Pulmonary Arterial Hypertension Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Endothelin Receptor Antagonists (ERAs)
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators

Global Pulmonary Arterial Hypertension Market Size by Type & CAGR (2026-2033)

Market Overview
Branded
Generics

Global Pulmonary Arterial Hypertension Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Intravenous/ subcutaneous
Inhalational

Global Pulmonary Arterial Hypertension Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospitals
Retail Pharmacies
Online Pharmacies

Global Pulmonary Arterial Hypertension Market Size & CAGR (2026-2033)

North America (Drug Class, Type, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Drug Class, Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

United Therapeutics Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alembic Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aerami Therapeutics Holdings Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Asklepion Pharmaceuticals LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Keros Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Liquidia Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferrer (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gossamer Bio (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments